 ORLANDO, Fla., March 16, 2021 PRNewswire -- Diverse Biotech, Inc. announced today that it has finalized a strategic transaction with Enveric Biosciences to license exclusive worldwide development and commercialization rights for five novel compounds to address the adverse side effects of cancer treatments. 